Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: A randomized, double-blind, placebo-controlled phase 2b trial

Luis Fayad, Stephen M. Ansell, Ranjana Advani, Bertrand Coiffier, Robert Stuart, Nancy L. Bartlett, Andres Forero-Torres, Kazimierz Kuliczkowski, David Belada, Edmund Ng, Jonathan G. Drachman

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Fingerprint

Dive into the research topics of 'Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: A randomized, double-blind, placebo-controlled phase 2b trial'. Together they form a unique fingerprint.

Medicine & Life Sciences